Vivo Ventures Announces the Closing of Vivo Ventures Fund VI, L.P., a $275M Life Science Venture Fund

Vivo Ventures Announces the Closing of Vivo Ventures Fund VI, L.P., a $275M Life Science Venture Fund

May 07, 2007

    PALO ALTO, Calif., May 7 /Xinhua-PRNewswire/ -- Vivo
Ventures, LLC. announced the closing of Vivo Ventures Fund
VI, L.P. (the "new Fund" or "Vivo VI")
at $275 million, which  brings the firm's total funds under
management to more than $650 million.  Drs. Frank Kung,
Edgar Engleman and Albert Cha, who managed Vivo Ventures
Fund V, L.P. are the managing members of the new Fund,
while Dr. Chen Yu, previously a Principal, was promoted to
Partner.  

    The new Fund will follow the same general approach as
Vivo's prior funds and invest in companies developing and
commercializing therapeutic products -- drugs and devices
that treat human disease. Since Vivo's inception in 1997,
the funds have invested in 50 such companies, typically
leading or co-leading their first institutional rounds. 
The new Fund will invest mainly in private companies in the
U.S.  Vivo VI will also invest in public therapeutics
companies, as have all of the previous Vivo funds, and in
companies outside the U.S.

    Investors in the new Fund include university
endowments, foundations, funds of funds, financial
institutions, family offices and pension funds. In addition
to investors from the U.S. and Asia that had participated in
Vivo's earlier funds, Vivo VI added a number of new
institutional investors from the U.S. and Europe.


    For more information, please contact: 

    Dr. Chen Yu of Vivo Ventures
    Tel: [phone]